Italian guidelines for management and treatment of hyperbilirubinaemia of newborn infants ≥ 35 weeks’ gestational age

Italian Journal of Pediatrics

Carlo Dani²  Enrico Zecca¹  Letizia Capasso³  Francesco Raimondi³  Simone Pratesi²  Giovanni Barone¹  Costantino Romagnoli¹ 

[1]Division of Neonatology, Department of Pediatrics, Catholic University S H, Largo A. Gemelli, 8, Rome 00168, Italy

[2]Section of Neonatology, Department of Surgical and Medical Critical Care, Careggi University, Hospital of Florence, Florence, Italy

[3]Department of Pediatrics, Federico II University of Naples, Corso Umberto I, 40, Napoli 80138, Italy

关键词: Guidelines;    Discharge;    Newborn;    Jaundice;    Hyperbilirubinaemia;   

Others  :  805082
DOI  :  10.1186/1824-7288-40-11

 received in 2014-01-27, accepted in 2014-01-27,  发布年份 2014

【 摘 要 】

Hyperbilirubinaemia is one of the most frequent problems in otherwise healthy newborn infants. Early discharge of the healthy newborn infants, particularly those in whom breastfeeding is not fully established, may be associated with delayed diagnosis of significant hyperbilirubinaemia that has the potential for causing severe neurological impairments. We present the shared Italian guidelines for management and treatment of jaundice established by the Task Force on hyperbilirubinaemia of the Italian Society of Neonatology.

The overall aim of the present guidelines is to provide an useful tool for neonatologists and family paediatricians for managing hyperbilirubinaemia.

【 授权许可】

   
2014 Romagnoli et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 5.

【 参考文献 】

• [1]Maisels MJ, Kring E: Length of stay, jaundice, and hospital readmission. Pediatrics 1998, 101:995-998.
• [2]Friedman MA, Spitzer AR: Discharge criteria for the term newborn. Pediatr Clin North Am 2004, 51:599-618. viii
• [3]Mercier CE, Barry SE, Paul K, Delaney TV, Horbar JD, Wasserman RC, Berry P, Shaw JS: Improving newborn preventive services at the birth hospitalization: a collaborative, hospital-based quality-improvement project. Pediatrics 2007, 120:481-488.
• [4]Lee KS, Perlman M, Ballantyne M, Elliott I, To T: Association between duration of neonatal hospital stay and readmission rate. J Pediatr 1995, 127:758-766.
• [5]Seidman DS, Stevenson DK, Ergaz Z, Gale R: Hospital readmission due to neonatal hyperbilirubinemia. Pediatrics 1995, 96:727-729.
• [6]Dani C, Poggi C, Barp J, Romagnoli C, Buonocore G: Current Italian practices regarding the management of hyperbilirubinaemia in preterm infants. Acta Paediatr 2011, 100:666-669.
• [7]American Academy of Pediatrics Subcommittee on H: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004, 114:297-316.
• [8]Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF: Hyperbilirubinemia in the newborn infant > or =35 weeks’ gestation: an update with clarifications. Pediatrics 2009, 124:1193-1198.
• [9]Bhutani VK, Committee on F, Newborn, American Academy of P: Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011, 128:e1046-e1052.
• [10]National Institute of Child Health and Clinical Excellence 2011. http://pathways.nice.org.uk/pathways/neonatal-jaundice webcite
• [11]Atkinson M, Budge H: Review of the NICE guidance on neonatal jaundice. Arch Dis Child Educ Pract Ed 2011, 96:136-140.
• [12]Newman J: Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation) - Summary. Paediatr Child Health 2007, 12:401-418.
• [13]van Imhoff DE, Dijk PH, Hulzebos CV, Bartrial study group NNRN: Uniform treatment thresholds for hyperbilirubinemia in preterm infants: background and synopsis of a national guideline. Early Hum Dev 2011, 87:521-525.
• [14]Bratlid D, Nakstad B, Hansen TW: National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011, 100:499-505.
• [15]Kaplan M, Merlob P, Regev R: Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus. J Perinatol 2008, 28:389-397.
• [16]Newborn Service Clinical Guideline: Management of Neonatal Jaundice. http://www.adhb.govt.nz/newborn/guidelines/GI/Jaundice.htm webcite
• [17]Queensland Maternity and Neonatal Clinical Guideline: Neonatal Jaundice: Prevention, Assessment and Management. 2009. http://www.health.qld.gov.au/qcg/ webcite
• [18]Mishra S, Agarwal R, Deorari AK, Paul VK: Jaundice in the Newborn. AIIMS-NICU Protocols. 2007. http://www.newbornwhocc.org/ webcite
• [19]Rodriguez Miguelez JM, Figueras Aloy J, Association Espanola de Pediatria: Ictericia Neonatal. http://www.aeped.es/documentos/protocolos-neonatologia webcite
• [20]Arlettaz R, Blumberg A, Buetti L, Fahnenstich H, Mieth D, Roth-Kleiner M: Assessment and treatment of jaundice newborn infants 35 0/7 or more weeks of gestation. Swiss Soc Neonatology 2007, 1-4. http://www.neonet.ch/assets/pdf/2006_Bili-Empfehlungen_e_final.pdf webcite
• [21]De Luca D, Romagnoli C, Tiberi E, Zuppa AA, Zecca E: Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry. Acta Paediatr 2008, 97:146-150.
• [22]Romagnoli C, Tiberi E, Barone G, De Curtis M, Regoli D, Paolillo P, Picone S, Anania S, Finocchi M, Cardiello V, Zecca E: Validation of transcutaneous bilirubin nomogram in identifying neonates not at risk of hyperbilirubinaemia: a prospective, observational, multicenter study. Early Hum Dev 2012, 88:51-55.
• [23]Romagnoli C, Tiberi E, Barone G, Curtis MD, Regoli D, Paolillo P, Picone S, Anania S, Finocchi M, Cardiello V, Giordano L, Paolucci V, Zecca E: Development and validation of serum bilirubin nomogram to predict the absence of risk for severe hyperbilirubinaemia before discharge: a prospective, multicenter study. Ital J Pediatr 2012, 38:6. BioMed Central Full Text
• [24]Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/?o=1025 webcite
• [25]Maisels MJ, Watchko JF: Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003, 88(6):F459-F463.
• [26]Watchko JF, Maisels MJ: Jaundice in low birthweight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed 2003, 88(6):F455-F458.
• [27]Moyer VA, Ahn C, Sneed S: Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med 2000, 154:391-394.
• [28]De Luca D, Zecca E, Zuppa AA, Romagnoli C: The joint use of human and electronic eye: visual assessment of jaundice and transcutaneous bilirubinometry. Turk J Pediatr 2008, 50:456-461.
• [29]Riskin A, Tamir A, Kugelman A, Hemo M, Bader D: Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia? J Pediatr 2008, 152:782-787. 787 e781-782
• [30]Knudsen A: The influence of the reserve albumin concentration and pH on the cephalocaudal progression of jaundice in newborns. Early Hum Dev 1991, 25:37-41.
• [31]Knudsen A, Brodersen R: Skin colour and bilirubin in neonates. Arch Dis Child 1989, 64:605-609.
• [32]Romagnoli C, Catenazzi P, Barone G, Giordano L, Riccardi R, Zuppa AA, Zecca E: BiliCheck vs JM-103 in identifying neonates not at risk of hyperbilirubinaemia. Ital J Pediatr 2013, 39:46. BioMed Central Full Text
• [33]Romagnoli C, Zecca E, Catenazzi P, Barone G, Zuppa AA: Transcutaneous bilirubin measurement: comparison of Respironics BiliCheck and JM-103 in a normal newborn population. Clin Biochem 2012, 45:659-662.
• [34]Bhutani VK, Johnson L, Sivieri EM: Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999, 103:6-14.
• [35]Yu ZB, Dong XY, Han SP, Chen YL, Qiu YF, Sha L, Sun Q, Guo XR: Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. Eur J Pediatr 2011, 170:185-191.
• [36]Varvarigou A, Fouzas S, Skylogianni E, Mantagou L, Bougioukou D, Mantagos S: Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia. Pediatrics 2009, 124:1052-1059.
• [37]Mills JF, Tudehope D: Fibreoptic phototherapy for neonatal jaundice. Cochrane Database Syst Rev 2001, 1:CD002060.
• [38]Barak M, Berger I, Dollberg S, Mimouni FB, Mandel D: When should phototherapy be stopped? A pilot study comparing two targets of serum bilirubin concentration. Acta Paediatr 2009, 98:277-281.
• [39]Kaplan M, Kaplan E, Hammerman C, Algur N, Bromiker R, Schimmel MS, Eidelman AI: Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Arch Dis Child 2006, 91:31-34.
• [40]Kemper K, Forsyth B, McCarthy P: Jaundice, terminating breast-feeding, and the vulnerable child. Pediatrics 1989, 84:773-778.
• [41]Martinez JC, Maisels MJ, Otheguy L, Garcia H, Savorani M, Mogni B, Martinez JC Jr: Hyperbilirubinemia in the breast-fed newborn: a controlled trial of four interventions. Pediatrics 1993, 91:470-473.
• [42]Alcock GS, Liley H: Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002, 3:CD003313.
• [43]Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP: Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 2004, 16:163-166.